Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2013
October 2013, Vol 4, No 8
October 2013, Vol 4, No 8
Community Oncology Practices Trying to Keep Afloat
By
Caroline Helwick
Community Oncology
October 2013, Vol 4, No 8
Hollywood, FL—There are perplexing considerations for community oncology practices under sequestration, but adapting to future practice models poses even bigger questions, according to Leonard H. Natelson, Chief Executive Officer of Hematology/Oncology Associates of Rockland, NY.
Read Article
FDG-PET Helps Predict Prostate Cancer Prognosis
By
Rosemary Frei, MSc
Personalized Medicine
,
Prostate Cancer
,
Solid Tumors
October 2013, Vol 4, No 8
Niagara Falls, Ontario—Researchers have determined that 18F-fluorodeoxyglucose (FDG) positron emission tomography (FDG-PET), a widely available and relatively inexpensive imaging modality, could be used to shape treatment plans for patients who have been diagnosed with high Gleason score prostate cancer.
Read Article
Molecular Test Identifies Patients at Risk for Early and Late Breast Cancer Recurrence
In the Literature
October 2013, Vol 4, No 8
A new study compared the ability of 3 modalities—the new Breast Cancer Index (BCI) molecular test, the 21-gene recurrence score known as Oncotype DX, and the immunohistochemical (IHC4) prognostic model—to predict early and late disease recurrence in patients with ER-positive, node-negative breast cancer (Sgroi DC, et al.
Lancet Oncol
. 2013;14:1067-1076).
Read Article
PD-1 Inhibitor Lambrolizumab Is Safe, Shows Durable Responses in Patients with Advanced Melanoma
In the Literature
October 2013, Vol 4, No 8
Lambrolizumab (previously known as MK-3475) is a humanized monoclonal immunoglobulin G4 antibody that blocks the programmed death 1 (PD-1) receptor and reactivates an immune response to the cancer cells.
Read Article
Large-Scale Oncology Pathways Program Reduces Drug and Hospitalization Costs
In the Literature
October 2013, Vol 4, No 8
The cost of cancer care continues to rise, and especially the cost of cancer drugs. Since their introduction in the 1990s, clinical pathways have demonstrated an improvement in the quality of care, while lowering costs in numerous clinical settings.
Read Article
Comparative Effectiveness Research Should Reap Benefits for Oncology Care
By
Audrey Andrews
Breast Cancer
,
Breast Cancer Symposium
,
Solid Tumors
October 2013, Vol 4, No 8
San Francisco, CA—Comparative effectiveness research (CER) is an important construct for identifying and summarizing the evidence on the effectiveness, safety, and overall value of alternative strategies in oncology care, said Gary H. Lyman, MD, MPH, Professor of Medicine, Duke University and the Duke Cancer Research Institute, Durham, NC, during the 2013 Breast Cancer Symposium.
Read Article
Current Patterns and Costs of Treating Patients with Metastatic Breast Cancer
By
Audrey Andrews
Breast Cancer
,
Breast Cancer Symposium
,
Solid Tumors
October 2013, Vol 4, No 8
San Francisco, CA—In a population of patients with metastatic breast cancer and Medicare Part D claims, the mean lifetime cost of treatment was approximately $102,000, according to a study presented at the 2013 Breast Cancer Symposium by Hope S. Rugo, MD, Director, Breast Oncology Clinical Trials Program, University of California, San Francisco.
Read Article
Role of Radiation and Imaging in DCIS Explained
By
Phoebe Starr
Breast Cancer
,
Breast Cancer Symposium
,
Solid Tumors
October 2013, Vol 4, No 8
San Francisco, CA—Management of ductal carcinoma in situ (DCIS) was the focus of 2 studies highlighted at a press conference before the 2013 Breast Cancer Symposium.
Read Article
For Oncologists, Some Food for Thought in the New Era of Healthcare Reform
By
Audrey Andrews
Breast Cancer
,
Breast Cancer Symposium
,
Solid Tumors
October 2013, Vol 4, No 8
San Francisco, CA—At the 2013 Breast Cancer Symposium, Lawrence N. Shulman, MD, Senior Vice President for Medical Affairs, Dana-Farber Cancer Institute, Boston, told oncologists that in the current era of healthcare reform, they will need to think beyond treatment outcomes, toxicities, and personal preferences.
Read Article
Second-Generation ALK Inhibitor Regresses Brain Metastases in Patients with Lung Cancer
By
Phoebe Starr
ESMO 2013 Conference
,
ESMO
October 2013, Vol 4, No 8
Amsterdam, The Netherlands—The novel ALK/EGFR inhibitor known as AP26113 achieved good responses in reducing brain metastases in patients with crizotinib (Xalkori)-resistant and crizotinib-nave non–small-cell lung cancer (NSCLC), as well as radiographic regression of central nervous system (CNS) metastases.
Read Article
Page 2 of 4
1
2
3
4
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Medication Assurance Programs, as Deceiving and Harmful as Alternate Funding Programs
Dawn Holcombe, MBA, FACMPE, ACHE
2.
Addressing Challenges to Adoption of Value-Based Agreements
Phoebe Starr
3.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma